eli lilly glp 1 injection Rolls Out Its GLP-1 Strategy Worldwide Novo Nordisk Sues Eli Lilly

Sept 16: After a three-month delay, the FDA handed GSK a victory Friday, approving momelotinibto be henceforth known as Ojjaarafor the treatment of myelofibrosis with anemia

But actually, there was one thing that we noted somewhat later

Eli Lilly intends to submit regulatory applications for orforgliprons approval in weight management by the end of 2025, followed by an application for type 2 diabetes in 2026

Also, the New York City Department of Educations Food Standards lists allulose, along with a wide range of zero-calorie and reduced-calorie sweeteners, among the prohibited ingredients

Lili Ladaga Editor Raki Swanson Tester Raki Swanson is a Minnesota-based freelance health writer and married mother to two adult children